To the Editor: My thanks to Drs. Metcalfe and Archibald for their supportive comments in their letter, “Fragile X Population Carrier Screening,”1 and for drawing attention to their earlier and ongoing studies on population-based carrier screening for fragile X (FMR1) trinucleotide repeat expansions. Although not explicitly stated in my commentary,2 what I had in mind, perhaps provincially, was National Institutes of Health– or professional organization–sponsored pilot studies in the US population, along the lines of the cystic fibrosis carrier screening pilot studies in the 1990s that set the stage for nationwide carrier screening for that disorder. The experiences of Metcalfe and Archibald in Australia, along with other fragile X screening pilots in Taiwan, Israel, Finland, and the United States as summarized in their earlier meta-analysis,3 are extremely valuable as we begin to formulate evidenced-based practice guidelines in this area.
References
Metcalfe SA, Archibald AD . Fragile X population carrier screening. Genet Med 2012, this issue.
Grody WW . Expanded carrier screening and the law of unintended consequences: from cystic fibrosis to fragile X. Genet Med 2011;13: 996–997.
Hill MK, Archibald AD, Cohen J, Metcalfe SA . A systematic review of population screening for fragile X syndrome. Genet Med 2010;12: 396–410.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grody, W. Response to Metcalfe and Archibald. Genet Med 14, 351 (2012). https://doi.org/10.1038/gim.2012.1
Published:
Issue Date:
DOI: https://doi.org/10.1038/gim.2012.1